CN1069024A - 用作降低血中胆甾醇药剂的取代的β-内酰胺化合物及其制备方法 - Google Patents

用作降低血中胆甾醇药剂的取代的β-内酰胺化合物及其制备方法 Download PDF

Info

Publication number
CN1069024A
CN1069024A CN92108760A CN92108760A CN1069024A CN 1069024 A CN1069024 A CN 1069024A CN 92108760 A CN92108760 A CN 92108760A CN 92108760 A CN92108760 A CN 92108760A CN 1069024 A CN1069024 A CN 1069024A
Authority
CN
China
Prior art keywords
lower alkyl
compound
phenyl
substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN92108760A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·宾内特
J·W·克拉达
T·K·蒂卢范加丹姆
谭宙宏
李君宁
T·麦阿里斯特
C·科隆
D·H·R巴顿
R·布雷斯罗
S·杜加
W·瓦卡罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1069024A publication Critical patent/CN1069024A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN92108760A 1991-07-23 1992-07-22 用作降低血中胆甾醇药剂的取代的β-内酰胺化合物及其制备方法 Pending CN1069024A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73442691A 1991-07-23 1991-07-23
US73465291A 1991-07-23 1991-07-23
US734,652 1991-07-23
US734,426 1991-07-23

Publications (1)

Publication Number Publication Date
CN1069024A true CN1069024A (zh) 1993-02-17

Family

ID=27112730

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92108760A Pending CN1069024A (zh) 1991-07-23 1992-07-22 用作降低血中胆甾醇药剂的取代的β-内酰胺化合物及其制备方法

Country Status (24)

Country Link
US (2) US5306817A (cg-RX-API-DMAC7.html)
EP (2) EP0596015B1 (cg-RX-API-DMAC7.html)
JP (1) JP2525125B2 (cg-RX-API-DMAC7.html)
CN (1) CN1069024A (cg-RX-API-DMAC7.html)
AT (1) ATE158789T1 (cg-RX-API-DMAC7.html)
AU (1) AU658441B2 (cg-RX-API-DMAC7.html)
BG (1) BG61118B2 (cg-RX-API-DMAC7.html)
CZ (1) CZ14294A3 (cg-RX-API-DMAC7.html)
DE (1) DE69222532T2 (cg-RX-API-DMAC7.html)
EE (1) EE9400342A (cg-RX-API-DMAC7.html)
ES (1) ES2107548T3 (cg-RX-API-DMAC7.html)
FI (1) FI940296A7 (cg-RX-API-DMAC7.html)
HU (1) HUT67341A (cg-RX-API-DMAC7.html)
IE (1) IE922374A1 (cg-RX-API-DMAC7.html)
IL (1) IL102582A0 (cg-RX-API-DMAC7.html)
MX (1) MX9204327A (cg-RX-API-DMAC7.html)
MY (1) MY131273A (cg-RX-API-DMAC7.html)
NO (1) NO940221D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ243669A (cg-RX-API-DMAC7.html)
OA (1) OA09878A (cg-RX-API-DMAC7.html)
SK (1) SK7994A3 (cg-RX-API-DMAC7.html)
TW (1) TW223059B (cg-RX-API-DMAC7.html)
WO (1) WO1993002048A1 (cg-RX-API-DMAC7.html)
YU (1) YU72092A (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1050830C (zh) * 1993-09-21 2000-03-29 先灵公司 氮杂环丁烷酮类化合物及其医药用途
CN1071745C (zh) * 1993-07-09 2001-09-26 先灵公司 合成氮杂环丁酮类化合物的方法
CN1083833C (zh) * 1994-11-18 2002-05-01 先灵公司 用作降胆固醇剂的硫取代的氮杂环丁烷酮类化合物
CN1090479C (zh) * 1992-12-23 2002-09-11 先灵公司 一种胆固醇生物合成抑制剂与一种β-内酰胺胆固醇吸收抑制剂的联合
CN100522159C (zh) * 2001-01-26 2009-08-05 先灵公司 取代的氮杂环丁烷酮化合物在制备治疗谷甾醇血症的药物中的应用
CN103254107A (zh) * 2013-05-09 2013-08-21 东华大学 一种依泽替米贝类似物及其制备方法
CN103524486A (zh) * 2013-09-18 2014-01-22 中国科学院昆明植物研究所 N-喹啉基取代的β-内酰胺类化合物及其药物组合物和合成方法与应用

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
CA2139104A1 (en) * 1992-06-26 1994-01-06 Michael P. Deninno Steroidal glycosides for treating hypercholesterolemia
CA2106840A1 (en) * 1992-09-25 1994-03-26 Marco Baroni Heteroarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
JP3023179B2 (ja) * 1995-09-27 2000-03-21 シェーリング コーポレイション 立体選択的微生物還元プロセス
JPH11515025A (ja) 1995-11-02 1999-12-21 ワーナー−ランバート・コンパニー 脂質濃度を調節するための方法および医薬組成物
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
IL126696A0 (en) * 1996-04-26 1999-08-17 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
MEP27808A (en) * 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
AU2002258605B2 (en) 2001-03-28 2006-01-12 Merck Sharp & Dohme Corp. Enantioselective synthesis of azetidinone intermediate compounds
EP1417187A1 (en) 2001-07-16 2004-05-12 Euro-Celtique S.A. Aryl substituted thiazolidinones and the use thereof
MXPA04002572A (es) * 2001-09-21 2004-05-31 Schering Corp Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003254261B2 (en) * 2002-07-30 2008-04-17 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
AU2003291227A1 (en) 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1832576A1 (en) * 2003-11-10 2007-09-12 Microbia Inc. 4-Biarylyl-1-phenolyzetidin-2-ones
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
WO2005113496A1 (de) * 2004-05-21 2005-12-01 Sanofi-Aventis Deutschland Gmbh Verfahren zur herstellung von 1,4-diphenylazetidinon-derivaten
DE102004025072A1 (de) * 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
WO2006050634A1 (en) * 2004-11-15 2006-05-18 Xiamen Mchem Pharma (Group) Ltd. A preparation method of 1-(4-fluorophenyl)-(3r)-[3-(4-fluorophenyl)-(3s)-hydroxypropyl]-(4s)-(4-hydroxyphenyl)-2-azetidinone
EP1819684B1 (en) 2004-12-03 2013-08-07 Intervet International B.V. Substituted piperazines as cb1 antagonists
MX2007007473A (es) * 2004-12-20 2007-09-04 Schering Corp Procedimiento para la sintesis de azetidinonas.
EP1851197A2 (en) * 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
EP1877067A1 (en) * 2005-04-26 2008-01-16 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
CN101218213A (zh) * 2005-05-11 2008-07-09 迈克罗比亚公司 制备酚类4-联苯基氮杂环丁烷-2-酮的方法
US20090099355A1 (en) * 2005-05-25 2009-04-16 Microbia, Inc. Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
AU2006262441A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine H3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
CA2616058A1 (en) * 2005-09-08 2007-03-15 Vinod Kumar Kansal Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
US7514509B2 (en) * 2005-12-16 2009-04-07 Fina Technology, Inc. Catalyst compositions and methods of forming isotactic polyproyplene
WO2007084450A2 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
EP1986489A2 (en) 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
EP2059241A1 (en) * 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008108486A1 (ja) * 2007-03-06 2008-09-12 Teijin Pharma Limited １－ビアリールアゼチジノン誘導体
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
AU2008271178A1 (en) 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as CB1 antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
US20090093627A1 (en) * 2007-08-30 2009-04-09 Lorand Szabo Process for preparing intermediates of ezetimibe by microbial reduction
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
AU2010256360A1 (en) 2009-06-05 2012-01-12 Astrazeneca Ab Aminopyrrolidinone derivatives and uses thereof
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
CN103435525B (zh) * 2013-07-25 2015-11-18 凯莱英医药集团（天津）股份有限公司 一种制备依折麦布的方法
CN113801050B (zh) * 2021-09-27 2023-11-14 山东大学 一种多取代β-内酰胺类化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235913A (en) * 1977-06-07 1980-11-25 Pfizer Inc. 9-Hydroxyhexahydrodibeno[b,d]pyrans, 1-substituted-9-hydroxyhexahydrodibenzo]b,d]pyrans
CA1184175A (en) * 1981-02-27 1985-03-19 Walter Hunkeler Imidazodiazepines
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
DK476885D0 (da) * 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US4870169A (en) * 1985-07-17 1989-09-26 President And Fellows Of Harvard College Intermediates for beta-lactam antibiotics
US4845229A (en) * 1985-09-25 1989-07-04 University Of Notre Dame Du Lac Process for intermediates to 1-carbapenems and 1-carbacephems
US4745201A (en) * 1985-09-25 1988-05-17 University Of Notre Dame Du Lac Process for intermediates to 1-carbapenems and 1-carbacephems
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
FR2640621B1 (fr) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1090479C (zh) * 1992-12-23 2002-09-11 先灵公司 一种胆固醇生物合成抑制剂与一种β-内酰胺胆固醇吸收抑制剂的联合
CN1071745C (zh) * 1993-07-09 2001-09-26 先灵公司 合成氮杂环丁酮类化合物的方法
CN1050830C (zh) * 1993-09-21 2000-03-29 先灵公司 氮杂环丁烷酮类化合物及其医药用途
CN1083833C (zh) * 1994-11-18 2002-05-01 先灵公司 用作降胆固醇剂的硫取代的氮杂环丁烷酮类化合物
CN100522159C (zh) * 2001-01-26 2009-08-05 先灵公司 取代的氮杂环丁烷酮化合物在制备治疗谷甾醇血症的药物中的应用
CN103254107A (zh) * 2013-05-09 2013-08-21 东华大学 一种依泽替米贝类似物及其制备方法
CN103254107B (zh) * 2013-05-09 2015-10-21 东华大学 一种依泽替米贝类似物及其制备方法
CN103524486A (zh) * 2013-09-18 2014-01-22 中国科学院昆明植物研究所 N-喹啉基取代的β-内酰胺类化合物及其药物组合物和合成方法与应用
CN103524486B (zh) * 2013-09-18 2016-03-02 中国科学院昆明植物研究所 N-喹啉基取代的β-内酰胺类化合物及其药物组合物和合成方法与应用

Also Published As

Publication number Publication date
US5306817A (en) 1994-04-26
MX9204327A (es) 1994-07-29
MY131273A (en) 2007-07-31
JP2525125B2 (ja) 1996-08-14
DE69222532T2 (de) 1998-02-26
CZ14294A3 (en) 1994-07-13
NO940221L (no) 1994-01-21
FI940296A0 (fi) 1994-01-21
OA09878A (en) 1994-09-15
EP0596015A1 (en) 1994-05-11
WO1993002048A1 (en) 1993-02-04
ATE158789T1 (de) 1997-10-15
FI940296A7 (fi) 1994-01-21
AU2398092A (en) 1993-02-23
DE69222532D1 (de) 1997-11-06
HU9400185D0 (en) 1994-05-30
YU72092A (sh) 1995-12-04
EP0596015B1 (en) 1997-10-01
NZ243669A (en) 1994-12-22
BG61118B2 (bg) 1996-11-29
TW223059B (cg-RX-API-DMAC7.html) 1994-05-01
JPH06508637A (ja) 1994-09-29
HUT67341A (en) 1995-03-28
US6093812A (en) 2000-07-25
IE922374A1 (en) 1993-01-27
AU658441B2 (en) 1995-04-13
EP0524595A1 (en) 1993-01-27
IL102582A0 (en) 1993-01-14
NO940221D0 (no) 1994-01-21
SK7994A3 (en) 1994-07-06
ES2107548T3 (es) 1997-12-01
EE9400342A (et) 1996-04-15

Similar Documents

Publication Publication Date Title
CN1069024A (zh) 用作降低血中胆甾醇药剂的取代的β-内酰胺化合物及其制备方法
CN1273467C (zh) β－内酰胺化合物、这些化合物的制备方法以及含有这些化合物的降血清胆固醇药
CN1103780C (zh) 用作降低血胆固醇药剂的糖取代2－氮杂环丁酮
CN1179945C (zh) 吲哚衍生物、其制备方法及用途
CN1055684C (zh) 取代的吡啶化合物的制备方法
CN1064682C (zh) 具有磷脂酶a2抑制活性的吡咯烷衍生物
CN1129604C (zh) 新的氨基酸衍生物及其作为凝血酶抑制剂的用途
CN1028529C (zh) 内亚苯基氧杂双环庚基取代的前列腺素类似物的制法
CN1037144A (zh) 用作为消炎剂和抗退化剂的新的取代的氮氧杂丁酮
CN1060841A (zh) 喹唑啉衍生物及其制备方法
CN1009645B (zh) 7-氧杂二环庚烷取代的二酰胺及其同种类前列腺素类似物制造方法
CN1909902A (zh) 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物
CN1068815A (zh) 用做抗炎及抗变性剂的新的取代氮杂环丁酮
CN1194580A (zh) 酮衍生物及其在医学上的应用
CN1290265A (zh) 凝血酶受体拮抗剂
CN1221738A (zh) 喹啉酮衍生物、其制备方法和抗变态反应剂
CN1170842C (zh) 新的脒基苄基胺衍生物及其作为凝血酶抑制剂的用途
CN1745065A (zh) 4－氧代－3－(1－氧代－1h－异喹啉－2－基乙酰氨基)－戊酸酯和酰胺衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
CN1304401A (zh) calcilytic化合物
CN1028639C (zh) 白三烯拮抗剂三环衍生物的制法
CN1011780B (zh) 苯氧基乙酸衍生物的制备方法
CN1291979C (zh) 咪唑化合物及其作为腺苷脱氨酶抑制剂的用途
CN1898219A (zh) 作为组织蛋白酶抑制剂的新的酮基噁二唑衍生物
CN1167670C (zh) 芳基羧酸和四唑衍生物
CN1068817A (zh) 吲哚类衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication